Evidence/Findings:
<p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">Based on record review, observation, and interview, the manager failed to ensure a medication was administered in compliance with a medication order, for two of two residents sampled. The deficient practice posed a risk if the resident experienced a change in condition due to improper administration of medication.</span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">Findings include:</span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">1. A review of R1's medical record revealed a current written service plan dated September 4, 2025. This service plan indicated R1 received medication administration. </span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">2. A review of R1’s September 2025 medication administration record (MAR) revealed the following: </span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Senna 8.6-50mg for Constipation.” This medication was administered from September 1, 2025, to September 29, 2025, at 8:00 am. </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Oxycodine Aceta 5-352 pain.” This medication was administered from September 1, 2025, to September 29, 2025, at 8:00 am, 1:00 pm, and 7:00 pm. </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">3. A review of R1's medical record revealed medication orders signed and dated by a medical practitioner on September 11, 2025, for the following: </span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Senna S by Mouth Tablet 8.6-50mg 1 Tablet twice a day PO Give 1 tablet by mouth twice a day for bowel care.” </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Oxycodine Acetaminophen by mouth tablet 5-352 mg 1 tablet twice a day PO Take 1 tablet (5mg/325mg) by mouth twice a day, scheduled for pain management.” </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">4. The Compliance Officers observed the following medication bottles:</span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Senna S” medication bottle was not available to review. </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Oxycodine Acetaminophen 5-352 mg.” </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">5. In an interview, E2 acknowledged that the MAR had the wrong dosage for “Senna S.” E2 reported that “Senna S” was given in the morning. E2 also acknowledged the frequency for “Oxycodine Acetaminophen 5-352 mg” was incorrect and that it was administered twice a day. </span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">6. A review of R2's medical record revealed a current written service plan dated July 4, 2025. This service plan indicated R2 received medication administration. </span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">7. A review of R2’s September 2025 MAR revealed the following: </span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Quetiapine 150 mg.” This medication was administered from September 1, 2025, to September 29, 2025, at 8:00 pm. </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Lactulose 10mg/15ml 3x a day.” This medication was administered from September 1, 2025, to September 29, 2025, at 8:00 am, 12:00 pm, and 5:00 pm. </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">8. A review of R2's medical record revealed medication orders signed and dated by a medical practitioner on September 11, 2025, for the following: </span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Seroquel by mouth tablet 100mg 100 milligram at bedtime PO.” </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Lactulose 20mg/30ml 3x a day PO.” </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">9. The Compliance Officers observed the following medication bottle:</span></p><ul><li><span style="font-size: 11pt; background-color: transparent;">“Quetiapine 100 mg Tab Take 1 and ½ by mouth at bedtime for sleep.” </span></li><li><span style="font-size: 11pt; background-color: transparent;">“Lactulose 10mg/15ml take 30ml by mouth 3x a day for constipation.” </span></li></ul><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">10. In an interview, E2 reported that E2 has been administering “Seroquel” and “Lactulose” per the MAR. </span></p><p><br></p><p><br></p><p><span style="font-size: 11pt; font-family: Arial, sans-serif; color: rgb(0, 0, 0); background-color: transparent;">11. In an exit interview, the findings were reviewed with E2, and no additional information was provided.</span></p>
Summary:
The following deficiencies were found during the on-site compliance inspection conducted on September 30, 2025: